MARCHF2 and metastatic neoplasm: Notably, data from TNM plot analysis [34] indicated that MARCH2 expression levels were higher in metastatic tumors compared to non-metastatic tumors in colon, esophageal, and pancreatic cancers (Fig. 7E).